Evaluating drug treatments for Parkinson's disease: how good are the trials?
Wheatley
Keith
K
Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2RR, UK. k.wheatley@bham.ac.uk
Stowe
Rebecca L
RL
Clarke
Carl E
CE
Hills
Robert K
RK
Williams
Adrian C
AC
Gray
Richard
R
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D002394:Catechol O-Methyltransferase